Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 7712 results

  1. Virtual Wards for COPD exacerbations

    Awaiting development [GID-MT608] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  2. The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound

    Awaiting development [GID-MT603] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  3. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia

    Awaiting development [GID-MT599] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  4. Cyanoacrylate glue for hernia mesh fixation

      Status ...

    Medical technologies guidance
    Topic selection

  5. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer ID6425

    Awaiting development [GID-TA11519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies

    In development [GID-HTE10055] Expected publication date: 23 June 2025

    Health technology evaluations
    In development

  8. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development [GID-TA10748] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours ID6511

    Awaiting development [GID-TA11659] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    In development [GID-TA10879] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ambulatory pulmonary artery pressure monitoring devices for heart failure

    In development [GID-DG10087] Expected publication date: 20 January 2026

    Diagnostics guidance
    In development

  14. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]

    In development [GID-TA11164] Expected publication date: 17 September 2025

    Technology appraisal guidance
    In development

  15. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development